HBM Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

HBM Holdings şirketinin toplam hissedar öz sermayesi $122.8M ve toplam borcu $65.0M olup, bu da borç-öz sermaye oranını 52.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $219.7M ve $96.9M dir. HBM Holdings 'in FAVÖK'ü $17.1M faiz karşılama oranı -6.7 dur. Şirketin $183.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

52.9%

Borç/özkaynak oranı

US$64.95m

Borç

Faiz karşılama oranı	-6.7x
Nakit	US$183.04m
Eşitlik	US$122.81m
Toplam yükümlülükler	US$96.90m
Toplam varlıklar	US$219.71m

Son finansal sağlık güncellemeleri

Recent updates

Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Oct 02

Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

Jul 18

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2142 'nin kısa vadeli varlıkları ( $202.9M ) kısa vadeli yükümlülüklerini ( $58.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2142 şirketinin kısa vadeli varlıkları ( $202.9M ) uzun vadeli yükümlülüklerini ( $38.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2142 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 2142 şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Borç Kapsamı: 2142 'nin borcu işletme nakit akışı ( 32.5% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 2142 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/30 07:51
Gün Sonu Hisse Fiyatı	2024/12/30 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

HBM Holdings Limited 7 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Bo Li	BofA Global Research
Tony Ren	CLSA
null null	Credit Suisse

HBM Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Recent updates

Investor sentiment improves as stock rises 16%

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

HBM Holdings Limited Announces Submission of Investigational New Drug Application for HBM9378\SKB378 (ANTI-TSLP) for COPD to the National Medical Products Administration of China

HBM Holdings Limited Appoints Yifan Gao as Joint Company Secretary

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Investor sentiment improves as stock rises 20%

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%

Harbour Biomed Announces the Latest Clinical Data on the First-In-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 At the Esmo Congress 2024

First half 2024 earnings released: EPS: US$0.002 (vs US$0.004 in 1H 2023)

HBM Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Harbour BioMed to Present the Latest Progress of the First-In-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 17%

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)